1. Home
  2. CVKD vs TNXP Comparison

CVKD vs TNXP Comparison

Compare CVKD & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CVKD
  • TNXP
  • Stock Information
  • Founded
  • CVKD 2022
  • TNXP 2007
  • Country
  • CVKD United States
  • TNXP United States
  • Employees
  • CVKD N/A
  • TNXP N/A
  • Industry
  • CVKD Medicinal Chemicals and Botanical Products
  • TNXP Biotechnology: Pharmaceutical Preparations
  • Sector
  • CVKD Health Care
  • TNXP Health Care
  • Exchange
  • CVKD Nasdaq
  • TNXP Nasdaq
  • Market Cap
  • CVKD 20.8M
  • TNXP 19.5M
  • IPO Year
  • CVKD 2023
  • TNXP N/A
  • Fundamental
  • Price
  • CVKD $16.17
  • TNXP $0.61
  • Analyst Decision
  • CVKD Strong Buy
  • TNXP Strong Buy
  • Analyst Count
  • CVKD 2
  • TNXP 2
  • Target Price
  • CVKD $46.00
  • TNXP $53.50
  • AVG Volume (30 Days)
  • CVKD 79.1K
  • TNXP 202.6M
  • Earning Date
  • CVKD 11-07-2024
  • TNXP 11-12-2024
  • Dividend Yield
  • CVKD N/A
  • TNXP N/A
  • EPS Growth
  • CVKD N/A
  • TNXP N/A
  • EPS
  • CVKD N/A
  • TNXP N/A
  • Revenue
  • CVKD N/A
  • TNXP $11,291,000.00
  • Revenue This Year
  • CVKD N/A
  • TNXP $64.71
  • Revenue Next Year
  • CVKD N/A
  • TNXP $24.49
  • P/E Ratio
  • CVKD N/A
  • TNXP N/A
  • Revenue Growth
  • CVKD N/A
  • TNXP 183.05
  • 52 Week Low
  • CVKD $5.40
  • TNXP $0.12
  • 52 Week High
  • CVKD $32.55
  • TNXP $14.08
  • Technical
  • Relative Strength Index (RSI)
  • CVKD 61.78
  • TNXP 75.02
  • Support Level
  • CVKD $10.65
  • TNXP $0.32
  • Resistance Level
  • CVKD $12.25
  • TNXP $0.72
  • Average True Range (ATR)
  • CVKD 1.68
  • TNXP 0.15
  • MACD
  • CVKD 0.32
  • TNXP 0.04
  • Stochastic Oscillator
  • CVKD 76.54
  • TNXP 39.61

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: